Laboratory Assessment for Polymyositis
For diagnosing polymyositis, a comprehensive panel of laboratory tests should include muscle enzymes (creatine kinase, LDH, AST, ALT, aldolase), inflammatory markers, myositis-specific antibodies, and tests to rule out alternative diagnoses. 1
Core Laboratory Tests
Muscle Enzyme Panel
- Creatine Kinase (CK): Primary marker, often markedly elevated in active disease 2, 3
- Lactate Dehydrogenase (LDH): Supporting marker of muscle damage
- Transaminases: AST (SGOT) and ALT (SGPT) are typically elevated
- Aldolase: May be elevated even when CK is normal in some cases
Inflammatory Markers
- Erythrocyte Sedimentation Rate (ESR): Elevated in approximately 55% of cases 4
- C-Reactive Protein (CRP): Often elevated during active disease
Myositis-Specific and Myositis-Associated Antibodies
- Anti-synthetase antibodies: Anti-Jo-1 (most common, 15-25% of cases) and other ARS antibodies 5
- Anti-Mi-2: Associated with classic dermatomyositis features
- Anti-SRP: Associated with necrotizing myopathy
- Anti-TIF1γ/α: Important for cancer screening (associated with malignancy in DM) 6, 5
- Anti-MDA5: Associated with rapidly progressive interstitial lung disease 5
- Anti-NXP-2: Associated with calcinosis and malignancy risk 5
Additional Important Laboratory Tests
Cardiac Assessment
Renal and Hepatic Function
- Renal function tests: BUN, creatinine
- Liver function tests: Beyond transaminases, check for other liver parameters
Differential Diagnosis Tests
- Complete blood count and blood film
- Infection screen: To rule out infectious myopathies
- Endocrine panel: Thyroid function tests, vitamin D levels
- Metabolic/mitochondrial myopathy tests: When presentation is atypical 1
- Urinalysis: Particularly if protein is suspected
Monitoring Parameters
- CK levels should be monitored regularly to assess disease activity and treatment response
- ESR and CRP for ongoing inflammatory activity
- Periodic reassessment of organ-specific tests based on clinical manifestations
Special Considerations
Cancer Screening
Risk factors for malignancy in polymyositis patients include:
- Older age, male gender
- Rapid onset of disease
- Elevated CK, CRP, and ESR
- Presence of specific antibodies (anti-TIF1γ, anti-NXP-2) 6, 5
Interstitial Lung Disease Assessment
- Pulmonary function tests including diffusion capacity should be performed in all patients 1, 2
- Patients with anti-synthetase antibodies have higher risk of ILD 5
Common Pitfalls to Avoid
- Relying solely on CK levels for diagnosis or monitoring - some patients may have normal CK despite active disease
- Failing to test for myositis-specific antibodies, which provide valuable prognostic information
- Not considering cardiac involvement, which can be life-threatening
- Overlooking associated malignancy, particularly in older patients
- Neglecting to assess for interstitial lung disease, a major cause of morbidity and mortality
When laboratory findings are inconclusive but clinical suspicion remains high, further evaluation with MRI, electromyography, and/or muscle biopsy should be considered to confirm the diagnosis 1, 2, 3.